XML 55 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versus Performance ​ Pay Versus Performance Table In accordance with the rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, we are providing the following information regarding the relationship between the “Compensation Actually Paid” to our CEO (also referred to as our “PEO”) and our other named executive officers (together, our “NEOs”) and certain financial performance measures for the Company. This information includes compensation information for our PEO and our NEOs, as well as information on our cumulative total shareholder return (“TSR”), the cumulative TSR of our peer group, our net income and our product revenues, net for the fiscal years listed below. For purposes of this section, “peer group” is defined as the Nasdaq Biotechnology Index, as further detailed in footnote 7 below.
Year | ​ | ​ | Summary Compensation Table Total for PEO ($)(1) | ​ | ​ | Compensation Actually Paid to PEO ($)(2)(3) | ​ | ​ | Average Summary Compensation Table Total for Non-PEO Named Executive Officers ($)(4) | ​ | ​ | Average Compensation Actually Paid to Non-PEO Named Executive Officers ($)(2)(5) | ​ | ​ | Value of Initial Fixed $100 Investment Based on: | ​ | ​ | Net Income ($ M) | ​ | ​ | Total Product Revenues ($ M)(8) | ​
​ | Total Shareholder Return ($)(6) | ​ | ​ | Peer Group Total Shareholder Return ($)(7) | ​
2024 | ​ | ​ | ​ | ​ | 17,459,546 | ​ | ​ | ​ | ​ | ​ | 25,233,510 | ​ | ​ | ​ | ​ | ​ | 5,906,668 | ​ | ​ | ​ | ​ | ​ | 8,882,222 | ​ | ​ | ​ | ​ | ​ | 79.10 | ​ | ​ | ​ | ​ | ​ | 113.84 | ​ | ​ | ​ | ​ | ​ | 32.6 | ​ | ​ | ​ | ​ | ​ | 3,618.9 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 16,659,526 | ​ | ​ | ​ | ​ | ​ | 7,842,731 | ​ | ​ | ​ | ​ | ​ | 7,843,705 | ​ | ​ | ​ | ​ | ​ | 6,405,428 | ​ | ​ | ​ | ​ | ​ | 71.91 | ​ | ​ | ​ | ​ | ​ | 115.42 | ​ | ​ | ​ | ​ | ​ | 597.6 | ​ | ​ | ​ | ​ | ​ | 3,165.2 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 16,669,368 | ​ | ​ | ​ | ​ | ​ | 15,972,264 | ​ | ​ | ​ | ​ | ​ | 5,750,911 | ​ | ​ | ​ | ​ | ​ | 5,496,116 | ​ | ​ | ​ | ​ | ​ | 91.98 | ​ | ​ | ​ | ​ | ​ | 113.65 | ​ | ​ | ​ | ​ | ​ | 340.7 | ​ | ​ | ​ | ​ | ​ | 2,746.9 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 14,444,265 | ​ | ​ | ​ | ​ | ​ | 6,228,229 | ​ | ​ | ​ | ​ | ​ | 5,217,889 | ​ | ​ | ​ | ​ | ​ | 1,847,797 | ​ | ​ | ​ | ​ | ​ | 84.06 | ​ | ​ | ​ | ​ | ​ | 126.45 | ​ | ​ | ​ | ​ | ​ | 948.6 | ​ | ​ | ​ | ​ | ​ | 2,322.0 | ​ | ​
2020 | ​ | ​ | ​ | ​ | 16,378,192 | ​ | ​ | ​ | ​ | ​ | 13,448,394 | ​ | ​ | ​ | ​ | ​ | 3,725,684 | ​ | ​ | ​ | ​ | ​ | 3,748,945 | ​ | ​ | ​ | ​ | ​ | 99.61 | ​ | ​ | ​ | ​ | ​ | 126.42 | ​ | ​ | ​ | ​ | ​ | (295.7) | ​ | ​ | ​ | ​ | ​ | 2,068.7 | ​ | ​
​ (1) The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for Hervé Hoppenot, our CEO. ​ (2) The amounts shown for “Compensation Actually Paid “ (CAP) have been calculated in accordance with SEC rules and represent amounts reported in the Summary Compensation Table with certain adjustments as described in footnotes 3 and 5 below. ​ (3) The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the “Compensation Actually Paid” for our PEO for each of the years presented: ​
Year | ​ | ​ | Reported Summary Compensation Table Total for PEO ($) | ​ | ​ | Reported Value of Equity Awards ($) | ​ | ​ | CAP of Equity Vesting during FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted prior to the current FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted during the current FY ($) | ​ | ​ | Compensation Actually Paid to PEO ($) | ​
2024 | ​ | ​ | ​ | ​ | 17,459,546 | ​ | ​ | ​ | ​ | ​ | (13,858,712) | ​ | ​ | ​ | ​ | ​ | 304,971 | ​ | ​ | ​ | ​ | ​ | 3,302,113 | ​ | ​ | ​ | ​ | ​ | 18,025,592 | ​ | ​ | ​ | ​ | ​ | 25,233,510 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 16,659,526 | ​ | ​ | ​ | ​ | ​ | (13,759,707) | ​ | ​ | ​ | ​ | ​ | (2,202,340) | ​ | ​ | ​ | ​ | ​ | (1,080,176) | ​ | ​ | ​ | ​ | ​ | 8,225,428 | ​ | ​ | ​ | ​ | ​ | 7,842,731 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 16,669,368 | ​ | ​ | ​ | ​ | ​ | (13,783,149) | ​ | ​ | ​ | ​ | ​ | 1,005,994 | ​ | ​ | ​ | ​ | ​ | 2,981,288 | ​ | ​ | ​ | ​ | ​ | 9,098,763 | ​ | ​ | ​ | ​ | ​ | 15,972,264 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 14,444,265 | ​ | ​ | ​ | ​ | ​ | (12,088,636) | ​ | ​ | ​ | ​ | ​ | (606,066) | ​ | ​ | ​ | ​ | ​ | (1,960,844) | ​ | ​ | ​ | ​ | ​ | 6,439,510 | ​ | ​ | ​ | ​ | ​ | 6,228,229 | ​ | ​
2020 | ​ | ​ | ​ | ​ | 16,378,192 | ​ | ​ | ​ | ​ | ​ | (13,832,247) | ​ | ​ | ​ | ​ | ​ | 2,043,085 | ​ | ​ | ​ | ​ | ​ | 127,113 | ​ | ​ | ​ | ​ | ​ | 8,732,251 | ​ | ​ | ​ | ​ | ​ | 13,448,394 | ​ | ​
​ (4) Our non-PEO Named Executive Officers for 2024 comprises of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2023 are comprised of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2021 and 2022 were comprised of Ms. Stamoulis, Dr. Stein, Ms. Maria E. Pasquale, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2020 were comprised of Ms. Stamoulis, Dr. Stein, Dr. Flannelly, and Dr. Vijay Iyengar. ​ (5) The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the Average Compensation Actually Paid for our non-PEO Named Executive Officers for each of the years presented: ​
Year | ​ | ​ | Reported Summary Compensation Table Total for Non-PEO NEOs ($) | ​ | ​ | Reported Value of Equity Awards ($) | ​ | ​ | CAP of Equity Vesting during FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted prior to the current FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted during the current FY ($) | ​ | ​ | Compensation Actually Paid to Non-PEO NEOs ($) | ​
2024 | ​ | ​ | ​ | ​ | 5,906,668 | ​ | ​ | ​ | ​ | ​ | (4,361,467) | ​ | ​ | ​ | ​ | ​ | 128,814 | ​ | ​ | ​ | ​ | ​ | 1,514,304 | ​ | ​ | ​ | ​ | ​ | 5,693,903 | ​ | ​ | ​ | ​ | ​ | 8,882,222 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 7,843,705 | ​ | ​ | ​ | ​ | ​ | (6,458,845) | ​ | ​ | ​ | ​ | ​ | (291,967) | ​ | ​ | ​ | ​ | ​ | 203,007 | ​ | ​ | ​ | ​ | ​ | 5,109,528 | ​ | ​ | ​ | ​ | ​ | 6,405,428 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 5,750,911 | ​ | ​ | ​ | ​ | ​ | (4,652,030) | ​ | ​ | ​ | ​ | ​ | 182,351 | ​ | ​ | ​ | ​ | ​ | 644,655 | ​ | ​ | ​ | ​ | ​ | 3,570,229 | ​ | ​ | ​ | ​ | ​ | 5,496,116 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 5,217,889 | ​ | ​ | ​ | ​ | ​ | (4,302,448) | ​ | ​ | ​ | ​ | ​ | (213,819) | ​ | ​ | ​ | ​ | ​ | (837,071) | ​ | ​ | ​ | ​ | ​ | 1,983,246 | ​ | ​ | ​ | ​ | ​ | 1,847,797 | ​ | ​
2020 | ​ | ​ | ​ | ​ | 3,725,684 | ​ | ​ | ​ | ​ | ​ | (2,791,502) | ​ | ​ | ​ | ​ | ​ | 218,828 | ​ | ​ | ​ | ​ | ​ | 534,106 | ​ | ​ | ​ | ​ | ​ | 2,061,829 | ​ | ​ | ​ | ​ | ​ | 3,748,945 | ​ | ​
​ (6) Total Shareholder Return is calculated as the sum of the difference between our share price at the end of each year shown and the beginning of the measurement period plus the cumulative amount of dividends for the investment period, assuming dividend reinvestment, divided by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019. ​ (7) The peer group used for calculating Peer Group Total Shareholder Return is the Nasdaq Biotechnology Index, which is used for determining performance of the relative total shareholder return component for the performance shares awards to the NEOs. ​ (8) Represents total product revenues, net, as disclosed in the Consolidated Statements of Operations in our Annual Reports on Form 10-K for the years ended December 31, 2024, 2023, 2022, 2021, and 2020. |  |  |  |
Company Selected Measure Name | Total Product Revenues |  |  |  |
Named Executive Officers, Footnote | (1) The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for Hervé Hoppenot, our CEO. (4) Our non-PEO Named Executive Officers for 2024 comprises of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2023 are comprised of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2021 and 2022 were comprised of Ms. Stamoulis, Dr. Stein, Ms. Maria E. Pasquale, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2020 were comprised of Ms. Stamoulis, Dr. Stein, Dr. Flannelly, and Dr. Vijay Iyengar. |  |  |  |
Peer Group Issuers, Footnote | (7) The peer group used for calculating Peer Group Total Shareholder Return is the Nasdaq Biotechnology Index, which is used for determining performance of the relative total shareholder return component for the performance shares awards to the NEOs. |  |  |  |
PEO Total Compensation Amount | $ 17,459,546 | $ 16,659,526 | $ 16,669,368 | $ 14,444,265 | $ 16,378,192
PEO Actually Paid Compensation Amount | $ 25,233,510 | 7,842,731 | 15,972,264 | 6,228,229 | 13,448,394
Adjustment To PEO Compensation, Footnote | (3) The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the “Compensation Actually Paid” for our PEO for each of the years presented: ​
Year | ​ | ​ | Reported Summary Compensation Table Total for PEO ($) | ​ | ​ | Reported Value of Equity Awards ($) | ​ | ​ | CAP of Equity Vesting during FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted prior to the current FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted during the current FY ($) | ​ | ​ | Compensation Actually Paid to PEO ($) | ​
2024 | ​ | ​ | ​ | ​ | 17,459,546 | ​ | ​ | ​ | ​ | ​ | (13,858,712) | ​ | ​ | ​ | ​ | ​ | 304,971 | ​ | ​ | ​ | ​ | ​ | 3,302,113 | ​ | ​ | ​ | ​ | ​ | 18,025,592 | ​ | ​ | ​ | ​ | ​ | 25,233,510 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 16,659,526 | ​ | ​ | ​ | ​ | ​ | (13,759,707) | ​ | ​ | ​ | ​ | ​ | (2,202,340) | ​ | ​ | ​ | ​ | ​ | (1,080,176) | ​ | ​ | ​ | ​ | ​ | 8,225,428 | ​ | ​ | ​ | ​ | ​ | 7,842,731 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 16,669,368 | ​ | ​ | ​ | ​ | ​ | (13,783,149) | ​ | ​ | ​ | ​ | ​ | 1,005,994 | ​ | ​ | ​ | ​ | ​ | 2,981,288 | ​ | ​ | ​ | ​ | ​ | 9,098,763 | ​ | ​ | ​ | ​ | ​ | 15,972,264 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 14,444,265 | ​ | ​ | ​ | ​ | ​ | (12,088,636) | ​ | ​ | ​ | ​ | ​ | (606,066) | ​ | ​ | ​ | ​ | ​ | (1,960,844) | ​ | ​ | ​ | ​ | ​ | 6,439,510 | ​ | ​ | ​ | ​ | ​ | 6,228,229 | ​ | ​
2020 | ​ | ​ | ​ | ​ | 16,378,192 | ​ | ​ | ​ | ​ | ​ | (13,832,247) | ​ | ​ | ​ | ​ | ​ | 2,043,085 | ​ | ​ | ​ | ​ | ​ | 127,113 | ​ | ​ | ​ | ​ | ​ | 8,732,251 | ​ | ​ | ​ | ​ | ​ | 13,448,394 | ​ | ​
Non-PEO NEO Average Total Compensation Amount | $ 5,906,668 | 7,843,705 | 5,750,911 | 5,217,889 | 3,725,684
Non-PEO NEO Average Compensation Actually Paid Amount | $ 8,882,222 | 6,405,428 | 5,496,116 | 1,847,797 | 3,748,945
Adjustment to Non-PEO NEO Compensation Footnote | (5) The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the Average Compensation Actually Paid for our non-PEO Named Executive Officers for each of the years presented:
Year | ​ | ​ | Reported Summary Compensation Table Total for Non-PEO NEOs ($) | ​ | ​ | Reported Value of Equity Awards ($) | ​ | ​ | CAP of Equity Vesting during FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted prior to the current FY ($) | ​ | ​ | CAP of Unvested Equity at FYE granted during the current FY ($) | ​ | ​ | Compensation Actually Paid to Non-PEO NEOs ($) | ​
2024 | ​ | ​ | ​ | ​ | 5,906,668 | ​ | ​ | ​ | ​ | ​ | (4,361,467) | ​ | ​ | ​ | ​ | ​ | 128,814 | ​ | ​ | ​ | ​ | ​ | 1,514,304 | ​ | ​ | ​ | ​ | ​ | 5,693,903 | ​ | ​ | ​ | ​ | ​ | 8,882,222 | ​ | ​
2023 | ​ | ​ | ​ | ​ | 7,843,705 | ​ | ​ | ​ | ​ | ​ | (6,458,845) | ​ | ​ | ​ | ​ | ​ | (291,967) | ​ | ​ | ​ | ​ | ​ | 203,007 | ​ | ​ | ​ | ​ | ​ | 5,109,528 | ​ | ​ | ​ | ​ | ​ | 6,405,428 | ​ | ​
2022 | ​ | ​ | ​ | ​ | 5,750,911 | ​ | ​ | ​ | ​ | ​ | (4,652,030) | ​ | ​ | ​ | ​ | ​ | 182,351 | ​ | ​ | ​ | ​ | ​ | 644,655 | ​ | ​ | ​ | ​ | ​ | 3,570,229 | ​ | ​ | ​ | ​ | ​ | 5,496,116 | ​ | ​
2021 | ​ | ​ | ​ | ​ | 5,217,889 | ​ | ​ | ​ | ​ | ​ | (4,302,448) | ​ | ​ | ​ | ​ | ​ | (213,819) | ​ | ​ | ​ | ​ | ​ | (837,071) | ​ | ​ | ​ | ​ | ​ | 1,983,246 | ​ | ​ | ​ | ​ | ​ | 1,847,797 | ​ | ​
2020 | ​ | ​ | ​ | ​ | 3,725,684 | ​ | ​ | ​ | ​ | ​ | (2,791,502) | ​ | ​ | ​ | ​ | ​ | 218,828 | ​ | ​ | ​ | ​ | ​ | 534,106 | ​ | ​ | ​ | ​ | ​ | 2,061,829 | ​ | ​ | ​ | ​ | ​ | 3,748,945 | ​ | ​
Compensation Actually Paid vs. Total Shareholder Return | Compensation Actually Paid Versus Total Shareholder Return 2020-2024 TSR is based on the Nasdaq Biotechnology Index, which is the peer group used for the relative TSR component of our Performance Shares awarded to our CEO and other NEOs. It is also the peer group used in the Stock Price Performance Graph furnished with our Annual Report that is delivered to our stockholders together with this Proxy Statement in connection with our Annual Meeting of Stockholders. Compensation Actually Paid is highly correlated with TSR, given that the values of the components of our executive equity compensation (stock options, restricted stock units and a portion of our performance share goals), depend on our stock price performance. |  |  |  |
Compensation Actually Paid vs. Net Income | Compensation Actually Paid Versus Net Income (Loss) 2020-2024 Incyte does not currently utilize GAAP net income (loss) as a metric in its incentive programs, given that it may include certain one-time/non-recurring items that could make it not reflective of the underlying performance of our business. |  |  |  |
Compensation Actually Paid vs. Company Selected Measure | Compensation Actually Paid Versus Total Products Revenues, 2020-2024 As previously discussed, our CEO and other NEOs’ Compensation Actually Paid is highly dependent on the absolute and relative stock price performance due to the significant portion of our compensation program linked to equity incentives. In addition, other metrics such as total product revenues (which account for a significant portion (40%) of the performance goals for our performance share (PSU) component of our executive officers’ equity compensation in 2021, 2022, and 2023), pipeline progression and regulatory approvals, are also important performance measures that we use to link our performance to compensation actually paid to our executive officers. |  |  |  |
Total Shareholder Return Vs Peer Group | Compensation Actually Paid Versus Total Shareholder Return 2020-2024 TSR is based on the Nasdaq Biotechnology Index, which is the peer group used for the relative TSR component of our Performance Shares awarded to our CEO and other NEOs. It is also the peer group used in the Stock Price Performance Graph furnished with our Annual Report that is delivered to our stockholders together with this Proxy Statement in connection with our Annual Meeting of Stockholders. Compensation Actually Paid is highly correlated with TSR, given that the values of the components of our executive equity compensation (stock options, restricted stock units and a portion of our performance share goals), depend on our stock price performance. |  |  |  |
Tabular List, Table | Financial Performance Measures The following table lists the most important performance measures that we used to link our performance to compensation actually paid to our named executive officers for the most recently completed fiscal year:
Most Important Performance Measures | ​
Total product revenues | ​
Pipeline development and progression | ​
Total shareholder return (TSR) | ​
Total Shareholder Return Amount | $ 79.1 | 71.91 | 91.98 | 84.06 | 99.61
Peer Group Total Shareholder Return Amount | 113.84 | 115.42 | 113.65 | 126.45 | 126.42
Net Income (Loss) | $ 32,600,000 | $ 597,600,000 | $ 340,700,000 | $ 948,600,000 | $ (295,700,000)
Company Selected Measure Amount | 3,618,900,000 | 3,165,200,000 | 2,746,900,000 | 2,322,000,000 | 2,068,700,000
PEO Name | Hervé Hoppenot |  |  |  |
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Total product revenues |  |  |  |
Non-GAAP Measure Description | (8) Represents total product revenues, net, as disclosed in the Consolidated Statements of Operations in our Annual Reports on Form 10-K for the years ended December 31, 2024, 2023, 2022, 2021, and 2020. |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Pipeline development and progression |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Total shareholder return (TSR) |  |  |  |
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (13,858,712) | $ (13,759,707) | $ (13,783,149) | $ (12,088,636) | $ (13,832,247)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 18,025,592 | 8,225,428 | 9,098,763 | 6,439,510 | 8,732,251
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 3,302,113 | (1,080,176) | 2,981,288 | (1,960,844) | 127,113
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 304,971 | (2,202,340) | 1,005,994 | (606,066) | 2,043,085
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (4,361,467) | (6,458,845) | (4,652,030) | (4,302,448) | (2,791,502)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 5,693,903 | 5,109,528 | 3,570,229 | 1,983,246 | 2,061,829
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,514,304 | 203,007 | 644,655 | (837,071) | 534,106
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 128,814 | $ (291,967) | $ 182,351 | $ (213,819) | $ 218,828

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |